HomeAI · summaries
Storia in 14 fonti
Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
- ·
cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
